The interactions of self-complementary oligonucleotides with a group of metal-mediated DNA‐binding drugs, including chromomycin A3, mithramycin and the novel compound UK-1, were examined via electrospray ionization quadrupole ion trap mass spectrometry. Both chromomycin and mithramycin were shown to bind preferentially to GC-rich oligonucleotide duplexes in a 2:1 drug:metal ratio, while UK-1 was shown to bind in a 1:1 drug:metal stoichiometric ratio without a strong sequence preference. These trends were observed in the presence of Co2+, Ni2+ and Zn2+, with the exception that chromomycin–Zn2+ complexes were not readily observed. The binding stoichiometries as well as the sequence specificities are in agreement with literature reports for solution studies. Binding selectivities and stabilities of the complexes were also probed using electrospray ionization mass spectrometry. Both of the GC-rich oligomers 5′-GCGCGC-3′ and 5′-GCGCATGCGC-3′ exhibited a binding preference for chromomycin over mithramycin in the presence of Co2+ and Ni2+. Energy-variable collisionally activated dissociation of the complexes was employed to determine the stabilities of the complexes. The relative metal-dependent binding energies were Ni2+ > Zn2+ > Co2+ for UK-1–oligomer complexes and Ni2+ > Co2+ for both mithramycin and chromomycin complexes.
Research into the function of docosahexaenoic acid (DHA; 22:6n-3), the predominant polyunsaturated fatty acid (PUFA) in the central nervous system (CNS), is often hindered by the difficulty in obtaining dramatic experimental decreases in DHA in the brain and retina of laboratory rats. In this study, the artificial rearing procedure, whereby infant rats are removed from their mothers, gastrostomized, and fed synthetic formula, was used in an attempt to produce rapid changes in CNS levels of DHA. Female rats were raised, from day 4-5 of life, on one of two formulas-one containing the essential fatty acids of both the n-6 and n-3 series in proportions approximately equal to those of rat milk, and the other containing high levels of 18:2n-6 but very little n-3 fatty acid. At weaning, both groups were given AIN-76A diets modified so that the PUFA content resembled that of the preweaning formula. At eight weeks of age, the n-3-deficient group exhibited decreases of more than 50% in total DHA content in the brain, accompanied by increases in arachidonic acid (AA) (20:4n-6) and, especially, docosapentaenoic acid (22:5n-6). Other artificially-reared rats were mated and their offspring were also maintained on the respective diets. In spite of the fact that they had been reared artificially, the rats mated successfully and reared litters with no obvious abnormalities. At both ten days of age and again at eight weeks, offspring of the n-3-deficient mothers exhibited decreases of more than 90% in total DHA content. Again, the long-chain n-6 PUFA increased proportionately so that total PUFA levels in the brain were not lower. As these differences are greater than those commonly reported, even after 2-3 generations of normal dietary deprivation in rodents, this procedure may be an important tool in the study of the effects of n-3 deficiency on neural development and, subsequently, of the function of DHA in nervous tissue.
The metabolic dependencies of cancer cells have substantial potential to be exploited to improve the diagnosis and treatment of cancer. Creatine riboside (CR) is identified as a urinary metabolite associated with risk and prognosis in lung and liver cancer. However, the source of high CR levels in patients with cancer as well as their implications for the treatment of these aggressive cancers remain unclear. By integrating multiomics data on lung and liver cancer, we have shown that CR is a cancer cell-derived metabolite. Global metabolomics and gene expression analysis of human tumors and matched liquid biopsies, together with functional studies, revealed that dysregulation of the mitochondrial urea cycle and a nucleotide imbalance were associated with high CR levels and indicators of a poor prognosis. This metabolic phenotype was associated with reduced immune infiltration and supported rapid cancer cell proliferation that drove aggressive tumor growth. CRhi cancer cells were auxotrophic for arginine, revealing a metabolic vulnerability that may be exploited therapeutically. This highlights the potential of CR not only as a poor-prognosis biomarker but also as a companion biomarker to inform the administration of arginine-targeted therapies in precision medicine strategies to improve survival for patients with cancer.
CD8+ T cells are master effectors of antitumor immunity, and their presence at tumor sites correlates with favorable outcomes. However, metabolic constraints imposed by the tumor microenvironment (TME) can dampen their ability to control tumor progression. We describe lipid accumulation in the TME areas of pancreatic ductal adenocarcinoma (PDA) populated by CD8+ T cells infiltrating both murine and human tumors. In this lipid-rich but otherwise nutrient-poor TME, access to using lipid metabolism becomes particularly valuable for sustaining cell functions. Here, we found that intrapancreatic CD8+ T cells progressively accumulate specific long-chain fatty acids (LCFAs), which, rather than provide a fuel source, impair their mitochondrial function and trigger major transcriptional reprogramming of pathways involved in lipid metabolism, with the subsequent reduction of fatty acid catabolism. In particular, intrapancreatic CD8+ T cells specifically exhibit down-regulation of the very-long-chain acyl-CoA dehydrogenase (VLCAD) enzyme, which exacerbates accumulation of LCFAs and very-long-chain fatty acids (VLCFAs) that mediate lipotoxicity. Metabolic reprogramming of tumor-specific T cells through enforced expression of ACADVL enabled enhanced intratumoral T cell survival and persistence in an engineered mouse model of PDA, overcoming one of the major hurdles to immunotherapy for PDA.
